Article

Prior glaucoma surgeries have minimal effect on DSEK outcomes

San Diego-Patients who have had prior glaucoma surgeries are not at significantly increased risk of negative visual outcomes if they then have Descemet's stripping endothelial keratoplasty (DSEK), according to Thasarat S. Vajaranant, MD, assistant professor, glaucoma service, University of Illinois at Chicago.

San Diego—Patients who have had prior glaucoma surgeries are not at significantly increased risk of negative visual outcomes if they then have Descemet’s stripping endothelial keratoplasty (DSEK), according to Thasarat S. Vajaranant, MD, assistant professor, glaucoma service, University of Illinois at Chicago.

“Little is known regarding elevated IOP and its effect on visual outcome after DSEK,” Dr. Vajaranant said.

She and her colleagues conducted a retrospective chart review of 399 DSEK procedures that were performed by a single surgeon. The patients were divided into three groups. Twenty-one of the patients had had prior glaucoma surgeries (trabeculectomies or shunt implantations) before the DSEK procedure. An additional 63 of the patients had glaucoma but no prior surgeries. The rest of the patients (315) did not have glaucoma.

At the 12-month follow-up post-DSEK, all three of the groups presented statistically significantly improved vision compared with baseline.

All three of the groups, however, also showed a sizable incidence of IOP elevation (>10 mm Hg from baseline) during the follow-up period. This increased incidence was higher among patients who had prior glaucoma surgeries (45%) than it was among patients who had glaucoma but no surgeries (39%) or no glaucoma (30%). Patients who had had prior glaucoma surgeries also were more likely to require additional anti-glaucoma medications and to require subsequent glaucoma-related procedures than the other two groups. For this reason, the researchers recommend close monitoring of IOP following DSEK.

“While glaucoma is a major risk factor for poor outcomes in penetrating keratoplasty, it does not appear to affect the visual outcomes in DSEK,” Dr. Vajaranant said.

This research was a collaborative effort between the University of Illinois and the Price Vision Group, Indianapolis, IN. Collaborators from the Price Vision Group, included Marianne O. Price, PhD and Francis W. Price, MD

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.